As trusted advisors to the world's largest and most innovative life sciences companies, we are well-positioned to support and help address the issues faced by pharmaceutical and biotech companies.
We have worked on a broad range of technology areas, including small molecules, biologics, biosimilars, human tissues, medical foods, dietary supplements, and nanotechnology across various therapy areas, including oncology, diabetes, immunology, cardiology, vaccines and rare disease.
Our team includes lawyers who have in-house experience working for big pharma and biotech companies, and who hold higher degrees in scientific areas like biochemistry, bioethics, biotechnology, chemistry, microbiology and plant pathology, molecular biology, molecular pharmacology and toxicology. They are members or leaders of pharmaceutical and biotech trade associations like AusBiotech, Hong Kong Association of Pharmaceutical Industry (HKAPI), Hong Kong Genome Institute (HKGI), Singapore Association of Pharmaceutical Industries, Thailand's Pharmaceutical Research and Manufacturers Association (PReMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), German Medicines Manufacturers' Association (BAH), Russia's Association of International Pharmaceutical Manufacturers (AIPM), Association of British Pharmaceutical Industry (ABPI), Pharmaceutical Research and Manufacturers of America (PhRMA), and the US Food and Drug Law Institute (FDLI).
We have advised on a wide range of high-profile and complex matters related to clinical trials, regulatory compliance, marketing and promotion, cross-border licensing and collaborations, mergers and acquisitions, supply chain arrangements, product liabilities, patent litigation and antitrust.
How We Can Help
Explores trends and opportunities in digital health from the perspective of three key players in the ecosystem: healthcare and life sciences organizations, technology companies and investors